FOLFOXIRI plus panitumumab for left-sided RAS-wild-type metastatic colorectal cancer
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag320 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2026. Verfasst von Howard S Hochster und 13 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Cancer Institute, New Brunswick, NJ 08901, United States. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Panitumumab. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Colorectal cancer (CRC) can be effectively treated with fluoropyrimidine chemotherapy doublets. The triplet chemotherapy program, FOLFOXIRI, is more effective than a doublet in randomized trials. We combined this triplet with the anti-epidermal growth factor receptor (EGFR) antibody, panitumumab, as first-line therapy in the appropriately targeted population: left-sided, RAS wild-type metastatic CRC.
Methods
A multicenter trial was conducted with the AGICC (Academic GI Cancer Consortium) group. Patients with stage IV or unresectable, left-sided, Rat Sarcoma Virus oncogene (RAS) wild-type CRC were eligible if they had measurable disease, adequate organ function, and Perfromance Status (PS) 0-1. Consented patients were treated with modified FOLFOXIRI and panitumumab every 2 weeks until progression or toxicity. CT scans were performed every 8 weeks. The primary endpoint was response rate by Response Evaluation Criteria in Solid Tumors (RECiST) v1.1, with an expectation of an RR ≥85%.
Results
Twenty-nine patients were enrolled and 27 were treated. A total of 430 cycles were given, including 7 patients with the maximum of 24 cycles (median 18, range 3-24). Best response included 2 CR, 18 PR, and 6 SD (RR 74%). One patient progressed at the time of first assessment. Grade 3+ toxicity included neutropenia, diarrhea, rash, hypomagnesemia, and hypokalemia, similar to prior reports. No patient had grade 5 toxicity. Median progression-free survival (PFS) was 17.0 months, and overall survival was not reached but exceeded 36 months.
Conclusion
In this small US multicenter study, utilizing FOLFOXIRI with an anti-EGFR antibody for appropriately selected patients, we note that the response rates and PFS values are among the highest reported in stage IV colon cancer. ClinicalTrials.gov identifier NCT04169347.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rutgers Cancer Institute, New Brunswick, NJ 08901, United States.
- Blatchford Analytics, Denver, CO 80201, United States.
- Yale Cancer Center, New Haven, CT 06520, United States.
- University of Kansas, Kansas City, KS 66160, United States.
- Swedish Cancer Institute, Seattle, WA 98122, United States.
- University of Arizona, Tucson, AZ 85719, United States.
ORCID-Profile: Howard S Hochster, Anup Kasi, Patrick M Boland
Zitieren
APA
Hochster, H. S., Blatchford, P. J., Stein, S., Lacy, J., Kasi, A., Boland, P. M., Gold, P., Scott, A. J., Oberstein, P., Cusnir, M., Rouse, K., Mallalieu, K., Saeed, A., & AGICC Group (2026). FOLFOXIRI plus panitumumab for left-sided RAS-wild-type metastatic colorectal cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyag320
Vancouver
Hochster HS, Blatchford PJ, Stein S, Lacy J, Kasi A, Boland PM, et al. FOLFOXIRI plus panitumumab for left-sided RAS-wild-type metastatic colorectal cancer. The Oncologist. 2026. doi:10.1093/oncolo/oyag320
BibTeX
@article{Hochster2026,
author = {Hochster, Howard S and Blatchford, Patrick J and Stein, Stacey and Lacy, Jill and Kasi, Anup and Boland, Patrick M and Gold, Philp and Scott, Aaron J and Oberstein, Paul and Cusnir, Michael and Rouse, Kate and Mallalieu, Karen and Saeed, Anwaar and AGICC Group, AGICC Group},
title = {FOLFOXIRI plus panitumumab for left-sided RAS-wild-type metastatic colorectal cancer},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag320}
}
EUVIMED